Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8141 of 8141 results

  1. Women's and reproductive health guidelines

    This webpage covers all NICE's guidelines on women's and reproductive health. The table presents the guidelines alphabetically. Updates planned or in...

    NICE guideline
    In development

  2. Depemokimab for treating severe eosinophilic asthma in people 12 years and over TSID 12017

    Awaiting development [GID-TA11553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Cardiovascular risk assessment and lipid modification

    Awaiting development [GID-QS10187] Expected publication date: TBC

    Quality standard
    Awaiting development

  4. News

    NICE and NHS England announce plan to enable innovative tech to be adopted quicker NHS patients in England will benefit from faster

  5. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued [GID-MT557]

    Medical technologies guidance
    Discontinued

  6. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued [GID-MT563]

    Medical technologies guidance
    Discontinued

  7. Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]

    In development [GID-TA11062] Expected publication date: 30 October 2024

    Technology appraisal guidance
    In development

  8. Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]

    Awaiting development [GID-TA11415] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  10. Single-step scaffold insertion for repairing symptomatic chondral knee defects

    Awaiting development [GID-IPG10364] Expected publication date: 17 September 2024

    Interventional procedures guidance
    Awaiting development

  11. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  12. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405

    In development [GID-HTE10035] Expected publication date: TBC

    Health technology evaluations
    In development

  13. NICE

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  14. Sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older [ID6440]

    In development [GID-TA11554] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments [ID6416]

    Awaiting development [GID-TA11520] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  16. Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway

    In development [GID-HTE10047] Expected publication date: TBC

    Health technology evaluations
    In development

  17. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  18. Abaloparatide for treating osteoporosis in postmenopausal women [ID882]

    In development [GID-TA10071] Expected publication date: 07 August 2024

    Technology appraisal guidance
    In development

  19. Robot-assisted surgery for orthopaedic procedures: early value assessment

    In development [GID-HTE10043] Expected publication date: 21 January 2025

    Health technology evaluations
    In development

  20. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    Awaiting development [GID-TA11366] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  21. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development [GID-TA11265] Expected publication date: TBC

    Technology appraisal guidance
    In development

  22. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development [GID-TA10568] Expected publication date: TBC

    Technology appraisal guidance
    In development

  23. Zoll ThermoGuard XP for Intravascular Temperature Management

      Status ...

    Medical technologies guidance
    Topic selection

  24. Natural Cycles for monitoring fertility

      Status ...

    Medical technologies guidance
    Topic selection

  25. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]

    In development [GID-TA10699] Expected publication date: TBC

    Technology appraisal guidance
    In development

  26. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]

    In development [GID-TA11187] Expected publication date: TBC

    Technology appraisal guidance
    In development

  27. Voxelotor for treating sickle cell disease [ID1403]

    In development [GID-TA10505] Expected publication date: 12 June 2024

    Technology appraisal guidance
    In development

  28. Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

    In development [GID-TA10893] Expected publication date: 31 July 2024

    Technology appraisal guidance
    In development

  29. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]

    In development [GID-TA11288] Expected publication date: TBC

    Technology appraisal guidance
    In development

  30. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  31. Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]

    In development [GID-TA11371] Expected publication date: 11 September 2024

    Technology appraisal guidance
    In development

  32. Avapritinib for treating advanced systemic mastocytosis ID3770

    In development [GID-TA11382] Expected publication date: TBC

    Technology appraisal guidance
    In development

  33. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  34. Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]

    In development [GID-TA11423] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  35. Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]

    In development [GID-TA11436] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  36. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

    In development [GID-TA10653] Expected publication date: 22 May 2024

    Technology appraisal guidance
    In development

  37. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]

    In development [GID-TA11389] Expected publication date: 19 June 2024

    Technology appraisal guidance
    In development

  38. Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis [ID3982]

    In development [GID-TA10873] Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Encorafenib with binimetinib for BRAF V600E mutation-positive advanced non-small-cell lung cancer ID6177

    In development [GID-TA11140] Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]

    In development [GID-TA11167] Expected publication date: 04 June 2024

    Technology appraisal guidance
    In development

  41. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development